There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Viral vector-based tools advance knowledge of basal ganglia anatomy and physiology.Journal of neurophysiology · 2016
   Review
2. Impact of age and vector construct on striatal and nigral transgene expression.Molecular therapy. Methods & clinical development · 2016
   Article

Corrections and comments

• Comment on
  AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction.2014

Authors and funding

4 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as